Rare diseases are often discussed in terms of science, genetics, and treatment pipelines. But when physicians talk about hypophosphatasia, or HPP, the conversation usually becomes much more practical very quickly.
Doctors talk about delayed diagnoses. Patients have been moving between specialists for years. Symptoms are being mistaken for something more common. Families are trying to understand a disease that most people, including many healthcare providers, rarely encounter in routine practice. And that is part of what continues to make HPP care so difficult in 2025.
Even though awareness has improved compared to a decade ago, many clinicians still describe the patient journey as inconsistent and fragmented, depending on where someone is diagnosed and which specialists they eventually reach.
Diagnosis is Still One of the Biggest Problems
One theme came up repeatedly in discussions around HPP care: patients are often identified much later than they should be. Part of the issue is that the disease can resemble several other skeletal or metabolic conditions. Symptoms may overlap with osteoporosis, arthritis, chronic pain disorders, or other bone-related abnormalities, especially in adults. Because of that, patients sometimes spend years treating symptoms without anyone recognizing the underlying cause.
Several physicians said that awareness remains uneven across specialties. Clinicians who regularly work with metabolic bone disorders tend to recognize the warning signs much earlier. Others may encounter only one or two potential HPP cases over an entire career. That difference in familiarity changes the speed of diagnosis considerably.
Genetic testing also came up often during conversations. Many specialists believe earlier testing could help reduce delays, especially in patients with unexplained fractures, persistent bone pain, or unusual dental and skeletal findings that do not fully align with more common diagnoses.
Treatment Has Improved, but Options Are Still Limited
Most physicians acknowledged that treatment availability has improved meaningfully over time, particularly with the introduction of enzyme replacement therapy for severe cases.
Several described ERT as one of the more important developments in this space because it gave patients and clinicians an option that moved beyond supportive management alone. At the same time, there was also caution in how doctors discussed current treatment pathways.
Many pointed out that long-term data remains relatively limited in certain patient groups, particularly adults living with HPP. Questions around durability, long-term disease management, and variability in treatment response are still being explored. And because HPP is rare, clinical experience itself can vary dramatically between providers.
Some specialists who regularly manage HPP patients described feeling comfortable navigating treatment decisions and monitoring strategies. Others admitted they rely heavily on referral networks or expert guidance because they simply do not encounter enough cases to build the same level of familiarity. That inconsistency affects patient access more than people sometimes realize.
Awareness Still Shapes the Patient Experience
One thing that stood out during discussions was how strongly physicians emphasized education. Not only physician education, but patient education too. Several clinicians mentioned that rare disease patients often spend years trying to advocate for themselves before receiving a confirmed diagnosis. By the time they reach the right specialist, frustration and uncertainty are already part of the experience.
Doctors also pointed out that communication between specialties still needs improvement. Endocrinologists, geneticists, orthopedists, rheumatologists, and primary care providers may all become involved at different stages, but coordination is not always seamless.
In practice, that means patients sometimes receive fragmented guidance even after diagnosis. Many physicians believe earlier collaboration between specialties could significantly improve continuity of care and reduce delays in treatment planning.
Why Speed Matters in Rare Disease Research
Another challenge with rare diseases is that gathering meaningful insights often takes time because patient populations are smaller and specialist access can be limited. Still, healthcare organizations are increasingly trying to shorten that gap between research and decision-making.
Firms involved in healthcare strategy and market intelligence, including CMI Consulting LLC, are seeing growing interest in rare disease research that captures physician experience, treatment barriers, and patient care gaps while those insights are still actionable. Because in rare diseases especially, delays in understanding often become delays in care.
Looking Ahead
Most physicians involved in HPP care agree on one thing: treatment progress alone will not solve every challenge patients face. Better awareness, earlier diagnosis, stronger referral pathways, and more consistent cross-specialty collaboration are just as important as new therapies entering the market.
And while HPP remains a difficult condition to manage in many settings, there is also a growing sense that the conversation around rare disease care is finally becoming broader and more practical. Not just about what treatments exist, but about how patients actually move through the healthcare system once symptoms begin. For many families living with HPP, that shift may matter just as much as the science itself.
Connect with our Experts
